Identifying treatment targets for a specific blood disorder caused by UBA1 mutations
Defining targetable vulnerabilities in UBA1-mutated VEXAS HSCs for clonal eradication
This study is looking at a rare condition called VEXAS syndrome to find out how changes in a specific gene affect blood stem cells, with the goal of discovering new ways to treat the condition by targeting the unhealthy cells while keeping the healthy ones safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11133840 on NIH RePORTER |
What this research studies
This research focuses on understanding a rare inflammatory disorder known as VEXAS syndrome, which is caused by mutations in the UBA1 gene found in blood stem cells. The study aims to develop advanced techniques to differentiate between mutated and healthy blood stem cells, allowing researchers to identify specific vulnerabilities in the mutated cells. By using innovative single-cell multi-omics approaches, the research seeks to uncover how these mutations lead to inflammation and other severe symptoms. This could ultimately lead to targeted therapies that can effectively eliminate the harmful mutated cells while preserving healthy ones.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with VEXAS syndrome or those exhibiting symptoms related to UBA1 mutations.
Not a fit: Patients without UBA1 mutations or those not affected by VEXAS syndrome are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted treatments for patients suffering from VEXAS syndrome, improving their quality of life and health outcomes.
How similar studies have performed: While the specific approach of using genotype-aware single-cell multi-omics is innovative, similar methodologies have shown promise in other areas of hematological research.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Beck, David — New York University School of Medicine
- Study coordinator: Beck, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.